J&J's Stelara nabs new EU, FDA approvals; GSK gets new indication for Revolade;

@FiercePharma: Top story on our website this A.M.: Who are the richest biopharma execs? Not all the usual suspects. Article | Follow @FiercePharma

> Johnson & Johnson's ($JNJ) Janssen unit said its arthritis drug Stelara won approval from the FDA to treat adults with psoriatic arthritis; it was previously approved for patients with moderate-to-severe plaque psoriasis. Report

> GlaxoSmithKline ($GSK) won a new indication in Europe for its Revolade drug, to treat low platelet counts in patients with chronic hepatitis C infection. Report

> Boehringer Ingelheim and Eli Lilly's ($LLY) Trajenta diabetes drug proved well tolerated in a broad variety of patients, including elderly patients with kidney problems, a study found. Report

> Sanofi's ($SNY) new diabetes drug Lyxumia delivered the best results as an add-on to basal insulin in Type 2 diabetes patients with well-controlled fasting blood sugar, a study found. Release

> The Chicago Mercantile Exchange says it will no longer accept delivery of Zilmax-treated cattle after Oct. 7; it's the latest organization to refuse cattle fed the Merck ($MRK) growth stimulant. Report

> Sanofi's new oral flea treatment for dogs, NexGard Chewables, won FDA approval. Release (PDF) | Report

> A new study found that cholesterol-fighting statin drugs may increase the risk of cataracts. Report

Medical Device News

@FierceMedDev: At AdvaMed, European regulations are on many CEOs' minds. Editor's corner | Follow @FierceMedDev

@MarkHFierce: The debt ceiling/budget fight has given an opening to device tax opponents. They hope for a repeal before year-end. More | Follow @MarkHFierce

@MichaelGFierce: Alnylam heralds positive results for RNAi amyloidosis drug. Story | Follow @MichaelGFierce

> Sequenom looks to unload analysis biz. Article

> Edwards wins FDA nod to expand Sapien label. Story

> Federal debt ceiling fight opens window for device tax opponents. Report

> Medtronic's tech halves atrial fibrillation risk. More

Biotech News

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Some folks might want to adjust their timelines on ARN-509. PhIII is coming. Item | Follow @JohnCFierce

@DamianFierce: Thanks to everyone cheering my trip to ! | Follow @DamianFierce

> SEC charges another biotech profiteer linked to insider trading scheme. More

> Ex-InterMune CEO's press-release pomp could leave legal legacy. Story

> AbbVie continues deal spree with $405M CF tie-up with Galapagos. News

Pharma Manufacturing News

@EricPFierce: After sales of Bydureon came up short, Bristol-Myers, AstraZeneca report manufacturing has too. Article | Follow @EricPFierce

> FDA warns Agila plant over torn gloves. Story

> Pharma squares off against compounders in lobbying fight. News

> J&J wins a bright spot after string of recalls. More

> FDA beefs up Indian staff in face of serious problems. Story

> U.K., Australia gather FDA intel on Ranbaxy ban. Report

Biotech Research News

@EmilyMFierce: $3.7M NIH program to fund biomedical research training. Item | Follow @EmilyMFierce

> Stem cell therapy protects vision in preclinical retinal disease study. More

> Pre-leukemia drug shows brain tumor regression in mice. News

> Stem cell reprogramming made easier by removing one protein. Report

> New compound kills tuberculosis bacterium in lab tests. Story

> NIH launches $45M Alzheimer's research effort, awards funds to 3 preclinical studies. Article

And Finally... A major study flagged sex differences in patients' blood-glucose control with Type 1 diabetes. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.